The phase 1/2, which has been initiated in Australia, will test the vaccine candidate in several hundred participants following the completion of enrolment.
The vaccine candidate was developed using SpyBiotech’s SpyCatcher/SpyTag protein “superglue” technology and a virus-like particle (VLP) from the Hepatitis B antigen as a carrier. The coronavirus spike protein is display on the VLP, which allows the properties of the “superglue” technology to induce an immune response in participants.
VLPs are already licensed for use in vaccines against Hepatitis B, and have encouraging safety and immunogenicity data in this indication.
“We are delighted to have dosed the first subjects in this trial with Serum Institute of India, the world’s largest vaccine manufacturer by number of doses produced, and to be advancing this COVID-19 vaccine candidate into clinical trials,” said Sumi Biswas, chief executive officer and co-founder of SpyBiotech…